Monogenic diabetes is frequently mistakenly diagnosed as either type 1 or type 2 diabetes, yet accounts for approximately 1-2% of diabetes. Identifying monogenic forms of diabetes has practical implications for specific therapy, screening of family members and genetic counselling. The most common forms of monogenic diabetes are due to glucokinase (GCK), hepatocyte nuclear factor (HNF)-1A and HNF-4A, HNF-1B, m.3243A4G gene defects. Practical aspects of their recognition, diagnosis and management are outlined, particularly as they relate to pregnancy. This knowledge is important for all physicians managing diabetes in pregnancy, given this is a time when previously unrecognised monogenic diabetes may be uncovered with careful attention to atypical features of diabetes misclassified as type 1, type 2, or gestational diabetes.
Introduction
The molecular diagnosis of monogenic forms of diabetes is important because it enables genetic counselling, predictive genetic testing in affected families, personalised medication and information regarding prognosis to be provided. Furthermore, these monogenic conditions shed light into the pathophysiology of the more prevalent metabolic syndrome (previously reviewed 1 ). This article will focus on the distinguishing clinical features and management of the most common monogenic causes of familial diabetes, with illustrative case histories. This knowledge is important for all physicians managing diabetes in pregnancy, given this is a time when previously unrecognised monogenic diabetes may be uncovered with careful attention to atypical features of diabetes misclassified as type 1, type 2, or gestational diabetes.
Diabetes is diagnosed by either elevated blood glucose or HbA1c values based on thresholds associated with a substantially increased risk of microvascular complications, particularly retinopathy among several cross-sectional epidemiology studies. 2 The thresholds for diagnostic fasting blood glucose is 7.0 mmol/L (126 mg/dL) or a 2 h blood glucose value after a 75 g oral glucose tolerance test of 11.1 mmol/L (200 mg/dL). 3 HbA1c levels of 6.5% (48 mmol/mol) or above are also diagnostic of diabetes. 3 Unless there are classic symptoms of hyperglycaemia or there is an associated random plasma glucose of 200 mg/dL or above, then the test needs to be repeated to confirm a diagnosis of diabetes. 3 Diabetes is classified into four clinical categories: type 1 diabetes (due to beta-cell destruction, leading to absolute insulin deficiency), type 2 diabetes (due to progressive insulin secretory defect on the background of insulin resistance), gestational diabetes (diabetes diagnosed during pregnancy that remits upon delivery) and other specific types of diabetes which include monogenic beta cell defects, genetic defects in insulin action, diseases of the exocrine pancreas and drug or chemical induced diabetes. Patients with type 1 diabetes typically present with hyperglycaemic symptoms of polyuria and polydipsia, and occasionally with diabetic ketoacidosis, with a clear requirement of insulin therapy to control glycaemia. Those with type 2 diabetes are frequently overweight, and typically respond to lifestyle changes, and various glucose lowering agents before requiring insulin therapy to control glycaemia. While all diabetes detected for the first time in pregnancy may be presumed to be gestational diabetes, a small proportion of these cases will subsequently require reclassification into type 1 diabetes, type 2 diabetes (either pre-existing or developing during pregnancy) or other types, based on failure to resolve post-partum. Difficulties in accurate classification of diabetes occur due to lack of cost-effective and reliable biomarkers of the underlying mechanistic defect in routine clinical practice and the epidemic of type 2 diabetes which accounts for approximately 95% of all patients with diabetes.
Monogenic beta-cell diabetes is thought to be responsible for approximately 2% of all diabetes cases diagnosed before the age of 45 years. 4 Approximately 80% of cases are misdiagnosed as either type 1 or type 2 diabetes, reflecting lack of physician awareness and / or access to genetic testing. 5 Clues to the diagnosis of monogenic forms of diabetes include lack of typical characteristics of type 1 diabetes (no pancreatic auto-antibodies, low or no insulin requirement five years after diagnosis, persistence of stimulated C-peptide4200 pmol/L, absence of diabetic ketoacidosis), or type 2 diabetes (lack of obesity, hypertension, dyslipidaemia), in the presence of a strong family history. 4 
Glucokinase
Those with a defect in one copy of their GCK gene have fasting hyperglycaemia that is present from birth 6 and show very little deterioration with age. 7 The typical glucose abnormality consists of mild, fasting hyperglycaemia (5.5-8 mmol/L), small excursions with oral glucose tolerance testing or meals (usually below 3.5 mmol/L) 8 and mild elevation in HbA1c (38-60 mol/L). 9 These biochemical abnormalities in otherwise asymptomatic individuals could represent prediabetes, type 2 diabetes, incipient type 1 diabetes or in the case of pregnancy, gestational diabetes mellitus (GDM).
Prediabetes is defined as elevated fasting glucose above 5.5 mmol/L, or HbA1c above 38 mmol/mol, which tends to progress over time, and leads to type 2 diabetes once the threshold of fasting glucose of 7 mmol/L or HbA1c of 48 mmol/mol is reached. Type 2 diabetes is also generally progressive, requiring initially dietary modification, and subsequently one to several glucose lowering therapies, including insulin. Type 1 diabetes generally presents dramatically with osmotic symptoms and very rapid rise in blood glucose levels necessitating insulin therapy, and prompt failure of other glucose lowering medications if these are trialled in the first instance. Gestational diabetes is first recognised in pregnancy, and resolves after delivery.
In the absence of deterioration of mild hyperglycaemia with time or failure to resolve after delivery, and the presence of similarly stable,
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University of Auckland, Auckland, New Zealand mild, fasting hyperglycaemia in a first-degree family member, a significant proportion will have a heterozygous mutation in GCK, which is inherited in an autosomal dominant manner. Very often the affected parent remains under-diagnosed or has been misdiagnosed with early onset type 2 diabetes, so confirming the presence of mild, fasting glucose in one parent can be a helpful clue when considering a diagnosis of a GCK mutation.
Women with this glucose abnormality are often identified during routine screening for GDM and misclassified as such. However, unlike GDM, women with a GCK defect have a stable derangement in their glucose metabolism, which does not resolve after delivery. Defects in GCK represent approximately 3% of Caucasian patients with gestational diabetes. 10 The combination of BMI 525 kg/m 2 and fasting glucose of 5.5 mmol/L or above, has been shown to have 68% sensitivity and 96% specificity for GCK. Using these criteria, the number of GDM women needed to test to find one case of GCK is 2.7. 11 GCK is an enzyme that is considered the glucose sensor of beta cells, as it catalyses the rate-limiting step of glucose phosphorylation and therefore enables the pancreatic beta cell to respond by secreting insulin that is appropriate to the degree of glycaemia. 12 An inactivating defect in one copy of the GCK gene results in a slightly higher fasting glucose set-point for glucose regulation. However, if both copies of the GCK gene are defective, then severe, permanent neonatal diabetes requiring insulin therapy results. 13 This occurs in the rare circumstance where both parents have GCK diabetes (more likely in consanguineous couples), when the risk of having a child with permanent neonatal diabetes is 25%, by inheriting two GCK mutations.
The clinical implication of confirming GCK-related diabetes is that it allows patients to be reassured that they have an inherited tendency to mild hyperglycaemia, which requires no specific glucose-lowering treatment or self-monitoring of blood glucose (outside of pregnancy), because microvascular or macrovascular complications are not expected. 14, 15 The near normal HbA1c in subjects with heterozygous GCK-related diabetes and lack of progression of hyperglycaemia are likely to explain the rarity of microvascular complications. 16, 17 In the Whitehall study, an increased risk of macrovascular disease was seen in patients with impaired glucose tolerance (IGT), so an increase might be expected in GCK subjects. 18 However, in contrast to IGT and prediabetes, patients with GCK mutations have normal fasting lipids, 16 are not significantly insulin resistant 19 and have less post-prandial hyperglycaemia. 20, 21 In pregnant women with GCK, the need to reduce maternal blood glucose to minimise fetal risk of macrosomia depends on the fetal GCK genotype, which will influence the fetus' sensing of maternal glucose. In 50% of cases, the fetus will not inherit the GCK mutation and will respond to maternal hyperglycaemia by excess insulin production and therefore excess growth (by approximately 550-700 g). Alternatively, if the fetus does inherit the GCK abnormality it will sense the maternal hyperglycaemia as normal, produce normal amounts of insulin and have normal growth. 22, 23 In this latter setting, aggressively lowering maternal glycaemia may adversely affect fetal growth. 24 As it is not currently possible to determine the fetal genotype non-invasively during pregnancy, decision on whether to treat maternal hyperglycaemia is made on the basis of monitoring fetal abdominal circumference and 475 th percentile being the recommended threshold to start insulin and normalise maternal glycaemia. 25 Fetal genotyping using cell-free fetal DNA from maternal plasma sampling during early pregnancy is currently being developed and may assist in appropriate glucose lowering therapy in women with GCK during pregnancy only when the fetus does not carry the GCK mutation.
Case 1: GCK related diabetes -Unnecessary therapy
Sue was diagnosed with ''type 2 diabetes'' at the age of 24 years during routine investigation for medical insurance purposes. Her fasting glucose was measured as 7.1 mmol/L and repeated at 7.2 mmol/L. She had a body mass index (BMI) of 20 kg/m 2 and was otherwise healthy.
After being advised to make lifestyle modifications metformin was started. While her BMI reduced to 18 kg/m 2 a year later, her HbA1c was noted to be consistently 51-52 mmol/mol and gliclazide 80 mg twice daily was added. Gliclazide was replaced with insulin when Sue became pregnant eight years later at the age of 36 years. She was treated with 54 units per day of insulin in the third trimester. Fetal growth scans showed normal growth with abdominal circumference just below the 50th percentile. She delivered a healthy baby girl with birthweight 2.8 kg at term. Post-partum, Sue was referred to the diabetes clinic where the diagnosis of a heterozygous GCK mutation was suspected. Her glutamic acid decarboxylase (GAD) and islet antigen 2 (IA2) antibodies were negative. She had no clinical features of insulin resistance with normal blood pressure 104/64 mm/Hg, normal lipids and no microvascular complications of diabetes. She had a strong family history of diabetes, affecting her mother (Lyn), her maternal uncle (Ron) and her maternal grandmother (see Figure 1 ). A heterozygous missense mutation in GCK gene was identified in Sue. Cascade testing of other affected family members (Lyn and Ron) confirmed this was also the aetiology of their diabetes. Sue, Lyn and Ron were each able to discontinue their glucose lowering therapies without impact on their respective glycaemia status. Predictive testing of Sue's daughter showed the presence of GCK, so in retrospect, insulin treatment during this pregnancy was not necessary.
HNF-1A
In subjects with hepatocyte nuclear factor (HNF)1A mutations, frank diabetes usually develops in adolescence or early adult life. The youngest age of onset of HNF-1A diabetes reported is four years, with 63% of patients having developed diabetes by the age of 25, 94% by age 50 and 99% by age 75. 26 In HNF1A mutation carriers, the fasting plasma glucose is initially normal, with elevated post-prandial glucose values, before developing severe hyperglycaemia in both fasting and postglucose load states. 21 While most cases are misdiagnosed as type 1 diabetes and started on insulin, features such as low insulin dose requirement, the absence of diabetic ketoacidosis despite periods without insulin and three generation family history of diabetes are clues for HNF-1A diabetes. In this case further tests to check for the persistence of C-peptide, absent pancreatic and GAD auto-antibodies 27 should be sought. If these criteria are present, then the prevalence of HNF-1A is approximately 10-20%. 28 Additional biomarkers suggestive of HNF-1A diabetes include low levels of highly-sensitive (hs) C-reactive protein (CRP) 29 and high levels of high-density lipoprotein (HDL) 30 which are helpful to use in combination with other clinical characteristics. A measurement of hsCRP below 0.75 mg/L has been reported to show modest 79% sensitivity and 70% specificity for distinguishing between HNF-1A and type 2 diabetes. 31 Elevated plasma HDL41.12 has been reported to be 75% sensitive and 64% specific for HNF-1A diabetes. 30 HNF-1A patients, like the HNF-1a knockout animals, are characterized by a low renal threshold and hence glycosuria. [32] [33] [34] Renal glycosuria has been shown to precede the development of diabetes and makes diabetes screening by urinary screening for glycosuria an appropriate and sensitive screening test for family members who have had a positive predictive genetic test for HNF-1A. 35 The patterns of microvascular complications are similar to that seen in type 1 diabetes, 36 therefore it is important to strive for good glycaemic control. HNF1A mutation carriers are at increased risk of cardiovascular mortality despite having a protective appearing lipid profile. 37 Statin therapy is recommended for HNF1A mutation carriers by the age of 40 years.
The clinical implication of making a diagnosis of HNF-1A diabetes is that this can frequently be treated with low dose oral sulfonylurea (SU) therapy. 38 Sulphonylureas (SU) bind to the sulfonylurea receptor subunit (SUR1) of the ATP-sensitive K þ (K ATP ) channel in the pancreatic beta cell and cause channel closure, allowing rise of the beta cell membrane potential, triggering opening of voltage-gated Ca 2þ entry and stimulation of insulin release. The action of SU therefore bypasses the major beta-cell defect arising from reduced HNF-1A function. Consequently, patients misdiagnosed as type 1 diabetes and treated with insulin can be switched to low-dose oral SU therapy once the genetic diagnosis of HNF-1A diabetes is made 39 with the majority expressing great relief at being insulin-free. 40 Glibenclamide treatment is recognised as safe in pregnancy, and given the superior and more stable control obtained by SU therapy, women generally choose to remain on this therapy rather than switch to insulin during pregnancy. Good control may be maintained for many years, although eventually some patients progress on to insulin treatment. Adjunctive treatment with oral DPP4 inhibitors has also been reported. 41, 42 HNF1A mutations may also predispose to familial liver adenomatosis through somatic inactivation of the remaining wild-type allele. 43 Patients with liver adenomatosis are at risk of haemorrhage and malignant transformation, however, the role of systematic screening of all patients with HNF-1A with liver ultrasound is unclear.
Case 2: HNF-1A diagnosis leads to change of therapy
A 22-year-old woman Erin was diagnosed with type 1 diabetes at the age of 22 years when she presented with fatigue and urinary tract infection and was found to have an elevated random blood glucose of 17 mmol/L. She was commenced on insulin but was not convinced, she needed to take it, and was insulin-free for over two years. Her brother, mother and maternal grandmother also had insulin treated diabetes (Figure 2) . Upon presentation to the diabetes clinic she had HbA1c 75 mmol/mol which had deteriorated from a level of 57 two years earlier. Her BMI was 22 kg/m 2 , her BP was normal at 124/82. Her fasting capillary glucose levels were 5-7 and her post-prandial tests were 15-18. GAD and islet cell antibody tests were negative. She had elevated HDL at 1.5 mmol/L and undetectable level of CRP (51) . Genetic testing found a mutation in HNF1A. This information enabled both Erin and her brother to stop taking insulin and to take gliclazide 40 mg once daily with improvement in glycaemic control to 55 mmol/L. Two of her brother's children also received pre-symptomatic genetic testing after genetic counselling. A positive result in one means this child can be monitored for glycosuria so that diabetes is diagnosed promptly and SU tablet commenced appropriately.
Erin went on to have a normal pregnancy after receiving genetic counselling that she had a 50% chance of passing on the HNF1A gene to her child. She was switched to glibenclamide 2.5 mg daily, and remained on this therapy during her pregnancy without complications of hyperglycaemia or hypoglycaemia. She had an uneventful delivery of a healthy baby girl at term. She chose not to have predictive genetic testing of her daughter.
HNF-4A
HNF-4A related diabetes is less common than HNF-1A, and results in a similar diabetic phenotype. In contrast to HNF-1A where there is no clinical manifestation at birth, HNF4A mutations can also cause neonatal hyperinsulinaemic hypoglycaemia. Approximately 50% of babies with HNF4A mutations are macrosomic (average increase in birth weight of 790 g compared with non-mutation carrying family members), suggesting increased insulin secretion in utero. 44 The neonatal hyperinsulinaemic hypoglycaemia is variable in severity and duration, with some patients requiring diazoxide therapy for several years. 45 Children with macrosomia and transient neonatal hypoglycaemia born to non-diabetic mothers should lead to evaluation of possible diabetes in the father and his family members. This is because both the father and the child may harbour unsuspected HNF4A mutation causing the macrosomia and transient neonatal hypoglycaemia phenotype, with development of diabetes in adolescence or early adulthood.
Reduced renal threshold for glucose is not observed in patients with HNF-4A and the biomarkers of reduced hsCRP and elevated HDL are not helpful in discriminating HNF-4A from type 2 diabetes. Figure 1 . Sue's family pedigree following genetic diagnosis of GCK mutation. The proband Sue indicated with an arrow was diagnosed with GCK first. Following this genetic diagnosis, other affected family members chose to have a genetic test. GCK mutations were found in her mother Lin, uncle Ron and cousins Brad and Ann. Sue's baby also had a predictive genetic test and was found to carry the GCK mutation.
Making a genetic diagnosis of HNF-4A (like HNF-1A) enables patients to be treated with oral SU therapy.
Case 3: HNF-4A diagnosis leads to change in therapy
Margaret was diagnosed with ''type 2 diabetes'' at the age of 16 years. She had a BMI of 23 kg/m 2 and normal lipids and blood pressure. She was treated with diet, metformin and then glibenclamide was added, until her first pregnancy at the age of 30 years. Glibenclamide was changed to insulin and she required approximately 60 units per day during her last trimester. She achieved HbA1c 50-60 mmol/mol during her pregnancy and delivered a healthy daughter by elective cesarean section at 38 weeks gestation with birthweight 3.9 kg at 38 weeks (þ2.2 standard deviation score (SDS)). During her second pregnancy, she achieved improved glycaemic control with HbA1c545 mmol/mol and delivered a healthy son by elective cesarean section at 35 weeks with birthweight 3.2 kg (þ3.2 SDS). He developed transient neonatal hypoglycaemia, which settled after two days. Upon review post-partum, Margaret had a mutation identified in HNF-4A. This mutation segregated with diabetes in all but one family member who also had features of type 2 diabetes (Figure 3 ). Margaret was able to switch from insulin therapy to 80 mg of gliclazide twice daily with maintenance of HbA1c around 52 mmol/mol. Predictive genetic testing of her children showed that her son also carried the HNF4A gene mutation, which was the reason for the increased birthweight and post-natal hypoglycaemia rather than maternal hyperglycaemia. Margaret was comfortable with the knowledge that she could be vigilant for early signs of diabetes in her son and prompt detection would lead to appropriate treatment with low dose SU therapy. 
HNF-1B
Mutations or deletions affecting the HNF1B gene is a frequent cause of renal developmental disorders and diabetes, and is identified in 25% of such patients. 46, 47 It is a less common cause of familial diabetes without renal disease. The most common renal manifestation is renal cysts, but renal dysplasia, single kidney and horseshoe kidneys have also been described. Genital tract malformations in combination with renal tract abnormalities such as bicornuate uterus, uterus didelphis, rudimentary uterus and vaginal atresia, have also been described. However, HNF-1B defects are not a frequent cause of women with isolated uterine abnormalities. 48 In addition, liver enzyme abnormalities, gout and pancreatic exocrine dysfunction may be seen, in keeping with the role of HNF-1B as a widely expressed transcription factor which plays a critical role in embryonic development of the kidney pancreas, liver and Mullerian duct. 47 Women with diabetes, who are also known to have renal tract and genital tract abnormalities should be screened for a deletion or mutation in HNF1B gene. Identifying HNF-1B in patients allows vigilance for associated features and genetic counselling regarding transmission to 50% of offspring. Diabetes generally requires insulin therapy.
m.3243A4G
The prevalence of m.3243A4G point mutation affecting mitochondrial DNA is estimated at around 1% of unselected population with diabetes. 49 The diabetes is most frequently associated with deafness and maternal family history of transmission from affected mothers to most offspring, but no transmission from affected fathers, hence the terminology ''maternal inherited diabetes and deafness'' (MIDD). The m.3243A4G mutation can also cause more severe manifestations such as mitochondrial encephalopathy, lactic acidosis and stroke-like episodes (MELAS) in some family members. Most affected members have short stature and slim body habitus. 49 Genetic testing for m.3243A4G point mutation is more sensitive when performed on buccal samples or urine rather than blood samples. 50, 51 The clinical implications of making this genetic diagnosis include genetic counselling of individuals so that fathers can be reassured they will not transmit this to their offspring, while female members are likely to do so. The treatment implications include supplementation with thiamine and coenzyme Q10 52 and avoidance of metformin due to a theoretical risk of inducing lactic acidosis. 49 Women with mitochondrial mutations have been reported to have excess miscarriages and preterm labour. 53 Magnesium sulphate toxicity has been reported when given as tocolysis to a woman with MIDD. 54
Case 4: MIDD diagnosis leads to change of therapy
Sandy was diagnosed with ''type 2 diabetes'' at the age of 36 years when she was found to have HbA1c of 65. She was short and slim (height 1.55 m and weight 42.4 kg, BMI 17.6). She also had hearing loss since 22 years of age and wore bilateral hearing aids. She had a very strong family history of diabetes (Figure 4 ). She was advised to make lifestyle changes, including modifying her diet and to increase her physical activity. She became exhausted after 1 h exercise sessions and developed prolonged muscle cramps. Retinal screening revealed pigmentary changes but no retinopathy or diabetic maculopathy. Genetic screening of a buccal swab showed the presence of m.3243A4G. She was treated with low dose SU, thiamine and coenzyme Q10 supplementation.
Conclusion
While the majority of diabetes first diagnosed in pregnancy will be gestational diabetes, or pre-existing type 1 or type 2 diabetes, knowledge of monogenic diabetes will help to correctly diagnose those who have atypical features. Taking an accurate family history is important, given that autosomal dominant family history of diabetes may be caused by monogenic disruption of GCK, HNF-1A, HNF-4A or HNF-1B. Those with a family history of MIDD may have inherited a mitochondrial point mutation (m.3243A4G). Consider the diagnosis of MIDD in the slim, short, deaf person with diabetes. Stable, mild, Figure 4 . Sandy's family pedigree following genetic diagnosis of mt.3243A4G mutation. The proband Sandy is indicated with an arrow. The age of each family member is shown below their square or circle symbol corresponding to male or female gender, respectively. Only Sandy was genetically tested and confirmed as being a mutation carrier (NM), while all her maternal family members were presumed to be obligate carriers of this mitochondrial point mutation.
fasting hyperglycaemia without a history of microvascular complications suggests GCK. Atypical features of type 1 diabetes include history of low insulin dose requirement, the absence of diabetic ketoacidosis despite periods without insulin and three generation family history of diabetes. In this case, persistence of C-peptide, and absence of pancreatic and GAD auto-antibodies should be checked, which would suggest genetic defects affecting HNF-1A or HNF-4A. The presence of biomarkers such as elevated HDL and low hsCRP is a clue for HNF-1A, while the additional history of macrosomia and transient neonatal hypoglycaemia in affected individuals are clues for HNF-4A defect. Women with diabetes, who are also known to have renal tract and genital tract abnormalities should be screened for a deletion or mutation in HNF1B gene.
Making a genetic diagnosis is important, as these subtypes have distinct management implications from more common forms of disease. Those with GCK usually require no glucose lowering therapy, outside of pregnancy. In pregnancy, insulin therapy is required in 50% cases, when the baby's growth is observed to be increased, indicating that the baby's genotype is wild-type. Those with HNF-1A and HNF-4A are generally best treated with oral SU therapy, often with increased sensitivity. Those with HNF-1B require insulin therapy as oral glucose lowering therapies are generally not efficacious or durable, and in those with MIDD, metformin therapy is not recommended due to theoretical concerns of increased lactic acidosis.
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